Marc Creus
CEO, TaBriX
Dr Marc Creus, interim CEO of TaBriX, has 20+ years experience in antibiotic development working as Chief Scientific Officer and Head of Business Development in various startups including Kherion Technology, Juvabis AG and Plusbiome AG. At the University of Basel he helped to establish the National Centre of Competence in Research “Antiresist” and has been Board Member of the Swiss Antibiotics Roundtable. Marc has a PhD from the Dept. Medicine at the University of Cambridge.